Nevertheless, our analysis reveals that intra-tumoral heterogeneity represented by the expression of both GLI1 and NANOG can help identify a subset of ERMS patients with worse outcome and therefore is clinically relevant. This evidence concerns the gene GLI1 and embryonal rhabdomyosarcoma.